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Porcine reproductive and respiratory syndrome virus (PRRSV)-induced pneumonia is a major problem, and
vaccination is used to reduce losses associated with PRRSV. Porcine circovirus type 2 (PCV2) causes lymphoid
depletion, and there is concern that this adversely affects the immune response. The objective of this study was
to investigate the effect of PCV2 infection on the efficacy of modified live virus (MLV) PRRSV vaccine.
Sixty-nine 2-week-old pigs were randomly assigned to one of seven groups of 9 to 10 pigs each. At 6 weeks of
age, pigs in groups 4, 5, and 6 were inoculated intranasally with PCV2 ISU-40895. At 8 weeks of age, groups
3, 4, 6, and 7 were vaccinated with a PRRSV MLV vaccine. At 12 weeks of age, groups 2, 3, and 4 were
challenged with PRRSV SDSU73. All pigs were necropsied 14 days after PRRSV challenge. PCV2-infected,
PRRSV-vaccinated, and PRRSV-challenged pigs had significantly (P < 0.05) more-severe macroscopic lung
lesions than did the PRRSV-vaccinated and PRRSV-challenged pigs that were not exposed to PCV2 prior to
PRRSV vaccination. Nonvaccinated PRRSV-infected pigs had a significantly (P < 0.001) higher incidence of
PRRSV antigen in lungs than did all other groups except the group infected with PCV2 prior to PRRSV
vaccination and challenge. The nonvaccinated PRRSV-challenged group and the group challenged with PCV2
prior to PRRSV vaccination and challenge had significantly (P < 0.001) lower average daily weight gain than
did the control and the vaccinated groups. This work suggests that PCV2 infection has an adverse effect on the
development of protective immunity induced by PRRSV vaccine.
Porcine circovirus type 2 (PCV2), a small, nonenveloped,
single-stranded DNA virus with a circular genome (48), is
ubiquitous in the global swine population (2). The hallmark
microscopic lesions of PCV2 infection are lymphoid depletion
and histiocytic replacement of lymphoid follicles in the lym-
phoid tissues and variable degrees of lymphohistiocytic inflam-
mation in a variety of organs (45). PCV2 is associated with
postweaning multisystemic wasting syndrome (PMWS) (1, 12),
which is characterized by moderate to excessive loss of body
condition often accompanied by respiratory disease in nursery
and grow-to-finish pigs (17). The incidence of PCV2-associ-
ated disease in affected herds generally varies from 4% to up to
30% in individual farms (2, 17, 23). On most farms, PCV2
infection is widespread and subclinical.
Studies on pigs with naturally acquired PMWS and PCV2
infection showed leukopenia characterized by decreased lym-
phocyte counts compared to those of healthy control pigs (10,
42, 43). Segale´s et al. (42) found a significant decrease in the
number of CD3 and CD4 cells in PMWS-affected pigs com-
pared to numbers in clinically healthy pigs, whereas no differ-
ence was found in the numbers of CD8 cells. Darwich et al.
(10) compared clinically PMWS-affected pigs that were in-
fected by PCV2, wasted pigs that were not infected by PCV2,
and healthy control pigs and found that, regardless of PCV2
infection status, wasted pigs in general had decreased CD4
cells. However, only PMWS-affected and PCV2-infected pigs
had decreased numbers of CD8 and double-positive cells.
The amount of PCV2 in lymphoid tissues was correlated to the
degree of lymphoid depletion and to the decrease in immuno-
globulin M-positive and CD8 cells in peripheral blood (10).
Further detailed assessment of PCV2-induced alteration of
cells of the immune system in pigs experimentally infected with
PCV2 demonstrated a PCV2-induced lymphopenia present
only in pigs that developed clinical PMWS but not in those that
were subclinically infected (29). The mean lymphocyte levels of
PCV2-infected pigs decreased below that of the control pigs,
which was most evident at 10 days postinoculation (DPI). A
prominent lymphopenia was present in PMWS-affected pigs
starting from DPI 14 until the death of the pigs. All T-cell
subpopulations were found to be susceptible to PCV2-induced
lymphopenia (29).
Lymphoid depletion is a necessary and hallmark lesion of
PCV2-associated PMWS (45); however, lymphoid depletion,
to some degree, can also be observed in subclinically infected
pigs (38). Studies on pigs with naturally acquired PMWS re-
vealed that there was a reduction in the number of interfol-
licular dendritic cells and a reduction or absence of B cells and
CD4 cells (40). Chianini et al. (8) graded lymphoid lesions in
pigs with natural PMWS as mild, moderate, and severe and
showed a reduction or loss of B and T lymphocytes. It has been
suggested that PCV2-associated lymphoid depletion compro-
mises the immune system of the pig. This is supported by case
reports describing PCV2 infection associated with coinfecting
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pathogens that are typically indicative of an immunosuppressed
stage of the host, such as Pneumocystis carinii (9), Chlamydia
spp. (6), pulmonary aspergillosis (44), and Cryptosporidium
parvum (30).
Porcine reproductive and respiratory syndrome virus
(PRRSV) is the major contributor to the porcine respiratory
disease syndrome complex (PRDC) in the United States (18)
and is estimated to cost the U.S. swine industry $560 million
annually (28). PRRSV is an enveloped, positive-sense, single-
stranded RNA virus classified in the order Nidovirales, family
Arteriviridae, genus Arterivirus (7). Clinical signs of PRRSV
infection in growing pigs include fever, sneezing, dyspnea,
tachypnea, anorexia, and decreased weight gain. Vaccination is
a common procedure to minimize economic losses associated
with this pathogen, and vaccines have proven to be effective in
experimental trials (33) and field studies (24, 47). However,
PRRSV vaccine failures are not uncommon in the field, and
PRRSV continues to be the most common primary pathogen
in cases of PRDC (18). PRRSV vaccine failure may be due to
lack of cross-protection between the vaccine and field strains
or failure of the pig to mount an effective response to PRRSV
vaccine.
The effect of PCV2 infection on PRRSV vaccine efficacy
has, to our knowledge, not been reported in the literature, and
the objective of this study was to investigate the effects of
PCV2 infection on the efficacy of a PRRSV modified live virus
(MLV) vaccine.
MATERIALS AND METHODS
Animals. Sixty-nine segregated, early weaned, specific-pathogen-free (SPF),
crossbred pigs were brought to the research facility at Iowa State University at
approximately 12 to 14 days of age. The pigs were purchased from a herd
determined to be free of PRRSV based on regular serological testing. PCV2-
associated disease was not observed in the source herd or the offspring of
this herd.
Housing and feeding. On the day of arrival at the research facility, the pigs
were randomly assigned to seven groups and rooms with 9 to 10 pigs in each
room. The pen size was 3 by 3.6 m, and each pen contained a nipple waterer and
one self-feeder. The rooms were identical in size and environmental controls.
The pigs were fed a complete, phased, corn- and soybean-based ration.
Experimental design, inoculations, and vaccination. The experimental design
is summarized in Table 1. Pigs were vaccinated with PRRSV MLV vaccine at 14
days after PCV2 infection when PCV2-associated lymphoid depletion is typically
most severe and the amount of PCV2 genomic copy numbers in serum is typically
highest in this experimental SPF pig model (32, 34, 36).
The experimental protocols were approved by the Iowa State University Com-
mittee on Animal Care. After waning of the passively acquired antibodies to
PCV2 at 6 weeks of age, pigs in groups 4, 5, and 6 were inoculated intranasally
with 3 ml of the PCV2 ISU-40895. At 8 weeks of age, pigs in groups 3, 4, 6, and
7 were vaccinated intramuscularly in the right side of the neck with 2 ml of the
Ingelvac PRRS ATP MLV vaccine (Boehringer Ingelheim Vetmedica, Inc., St.
Joseph, MO) according to the manufacturer’s recommendations. At 12 weeks of
age, each pig in groups 2, 3, and 4 received 2 ml of PRRSV SDSU73 intranasally.
PCV2 inoculum. The PCV2 virus stock was generated through direct trans-
fection of PK-15 cells with an infectious DNA clone of PCV2 ISU-40895 as
previously described (13). PCV2 isolate ISU-40895 was isolated in 1998 from a
wasting pig with respiratory disease in Iowa. The pig came from a group of 300
pigs with a history of increased respiratory disease and lethargy, with approxi-
mately 50% of the pigs affected (14). Inoculation was done with the PCV2 virus
stock at a dose of 105.2 50% tissue culture infective doses per ml.
PRRSV inoculum. Highly virulent PRRSV isolate SDSU73 was isolated from
a sow herd with a high prevalence of abortions and higher-than-usual sow
mortality in 1996 (26). Passage 2 of PRRSV SDSU73 (Courtesy of M. Roof,
Boehringer Ingelheim Vetmedica, Inc.) at a titer of 105 50% tissue culture
infective doses per ml was used for inoculation of the pigs.
Serology. Blood samples were collected on arrival of the pigs, followed by
weekly blood collections. Sera collected at 2 (arrival), 8 (PRRSV vaccination), 9,
10, 11, 12 (PRRSV inoculation), 13, and 14 (during necropsy) weeks of age were
tested for the presence of PRRSV-specific antibodies by a commercial PRRSV
enzyme-linked immunosorbent assay (ELISA) (HerdChek PRRSV antibody test
kit; Idexx Laboratories Inc., Westbrook, MA). An optical density at 405 nm
greater than or equal to 0.4 was set as the ELISA cutoff value. A fluorescent
focus neutralization assay to determine the amount of PRRSV SDSU73 neu-
tralizing antibodies was done on sera from all PRRSV-vaccinated groups (3, 4, 6,
and 7) collected on the day of vaccination and at 7, 14, 21, and 28 days postvac-
cination according to protocols used at the Iowa State University Veterinary
Diagnostic Laboratory.
Sera collected at 2 (arrival of the pigs), 6 (PCV2 inoculation), and 14 (nec-
ropsy) weeks of age were tested for the presence of PCV2-specific antibodies by
a PCV2 ELISA based on the recombinant ORF2 capsid protein of PCV2 (27).
Samples were considered positive if the calculated sample-to-positive (S/P) ratio
was 0.2 or greater.
Clinical evaluation. The pigs were monitored daily and scored for severity of
clinical respiratory disease ranging from 0 (normal) to 6 (severe dyspnea) and
abdominal breathing (16). In addition, pigs were evaluated daily for clinical signs,
including sneezing and jaundice. Rectal temperatures, wasting, and behavioral
changes such as lethargy were recorded daily. The pigs were weighed at weekly
intervals.
PCV2 DNA quantification. DNA extraction on sera collected at the day of
PRRSV challenge and at 14 days after PRRSV challenge, and on bronchoalveo-
lar lavage (BAL) fluid collected during necropsy, was performed using a
QIAamp DNA mini kit (QIAGEN, Valencia, CA). DNA extracts were used for
quantification of the amount of PCV2 genomic DNA by real-time PCR as
previously described (36).
PRRSV RNA detection and quantification. RNA extraction on sera col-
lected 7 and 14 days after PRRSV challenge and on bronchoalveolar lung
lavage fluid collected during necropsy was performed using a QIAamp viral
RNA mini kit (QIAGEN). Primer-probe combinations specific for the North
American PRRSV (PRRSORF7F [TGTCAGATTCAGGGAGRATAAGTT
AC], PRRSORF7R [ATCARGCGCACAGTRTGATGC], and PRRSORF7P
[6FAM-TGTGGAGTTYAGTYTGCC]) and the European PRRSV (LEL
YRTF [GCTGAAGATGACRTYCGGCA], LELYRTR [GCAGTYCCTGCG
CCTTGAT], and LELYRTP [VIC-TGCAATCGATYCAGAC]) were used for
the real-time, reverse transcriptase PCR (RT-PCR). Each PCR consisted of 2.5
l of the RNA template and 22.5 l of PCR master mix. The PCR master mix
contained 0.35 l of RT mix from a QuantiTect probe RT-PCR kit (QIAGEN)
with the magnesium chloride concentration adjusted to 6 mM. Forward and
reverse primers and detection probes were used at concentrations of 800, 800,
and 275 nM and 400, 400, and 100 nM for the North American and European
PRRSV, respectively. An additional 0.25 l (1.25 U) of HotStarTaq (QIAGEN)
was added to each reaction. Each reaction included five progressive 1:10 dilu-
tions of a known copy number of PRRSV that served to generate a standard
curve. Each plate was run in a sequence detection system (GeneAmp 7900;
Applied Biosystems) under company-specific conditions (30 min at 50°C, 15 min
at 95°C, followed by 35 cycles of 15 seconds at 94°C and 60 seconds at 60°C).
Necropsy. Necropsy was performed at 14 days after PRRSV challenge when
the pigs were 14 weeks old. Pathologists were blinded to the treatment group for
evaluation of gross lesions. The total amount of lung affected by pneumonia (0 to
100% of the lung affected by grossly visible pneumonia) was recorded for each
TABLE 1. Experimental design to determine the effect of PCV2
infection on the efficacy of PRRSV vaccine
Group no.
(n) Designation
a
Treatment at age (wk):
6 8 12
1 (10) Control
2 (9) NV-PRRSV PRRSV
3 (10) V-PRRSV Vaccinationb PRRSV
4 (10) PCV2-V-PRRSV PCV2 Vaccination PRRSV
5 (10) PCV2 PCV2
6 (10) PCV2-V PCV2 Vaccination
7 (10) V Vaccination
a NV, nonvaccinated; V, vaccinated.
b Ingelvac PRRS ATP MLV (Boehringer Ingelheim Vetmedica, Inc., St.
Joseph, MO).
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pig at necropsy in a blinded fashion as described previously (16). The scoring
system is based on the approximate volume that each lung lobe contributes to the
entire lung: the right cranial lobe, right middle lobe, cranial part of the left
cranial lobe, and the caudal part of the left cranial lobe contribute 10% each to
the total lung volume, the accessory lobe contributes 5%, and the right and left
caudal lobes contribute 27.5% each (16). The size of lymph nodes (score range
from 0 to 3: 0, normal; 1, two times the normal size; 2, three times the normal
size; and 3, four times the normal size) was estimated and recorded for each pig
(36). BAL fluid for bacterial and virologic examinations was collected as previ-
ously described using 50 milliliters of sterile phosphate-buffered saline for each
lung (25). Sections of lungs, lymph nodes (superficial inguinal, mediastinal,
tracheobronchial, and mesenteric), tonsil, thymus, ileum, kidney, colon, spleen,
and liver were collected at necropsy and fixed in 10% neutral-buffered formalin
and routinely processed for histological examination.
Histopathology. Microscopic lesions were evaluated in a blinded fashion. Lung
sections were scored for the presence and severity of interstitial pneumonia
ranging from 0 to 6 (0, normal; 1, mild multifocal; 2, mild diffuse; 3, moderate
multifocal; 4, moderate diffuse; 5, severe multifocal; and 6, severe diffuse) (16).
Sections of heart, liver, kidney, ileum, and colon were evaluated for the presence
of lymphohistiocytic inflammation and scored from 0 (none) to 3 (severe) (32).
Lymphoid tissues, including lymph nodes, tonsil, and spleen, were evaluated for
the presence of lymphoid depletion ranging from 0 (normal) to 3 (severe) and
histiocytic inflammation and replacement of follicles ranging from 0 (normal) to
3 (severe) (32).
IHC for detection of PRRSV and PCV2 antigens. Immunohistochemistry
(IHC) for detection of PRRSV-specific antigen was performed on formalin-fixed
and paraffin-embedded lung tissue sections as previously described (15). Simi-
larly, IHC for detection of PCV2-specific antigen was performed on formalin-
fixed and paraffin-embedded lung tissue sections using a rabbit polyclonal
antiserum as previously described (46).
Statistical analysis. Prior to data analysis, descriptive statistics were per-
formed to assess the overall quality of the data. Continuous data (weight, rectal
temperature, macroscopic lung lesions, and S/P ratios) were analyzed with a
one-way analysis of variance (ANOVA). If a one-way ANOVA was significant
(P  0.05), pairwise testing using Tukey’s adjustment was performed. Discrete
data (microscopic lesions and clinical observations) were analyzed by the non-
parametric Kruskal-Wallis one-way ANOVA. If the nonparametric ANOVA was
significant (P  0.05), Wilcoxon tests were used for pairwise testing. Response
feature analysis was performed to account for clinical observations. The obser-
vations obtained after PRRSV challenge were combined, and averages for each
pig and differences among groups were compared by using a nonparametric
Kruskal-Wallis ANOVA. Fisher’s exact test was used to evaluate differences in
incidences.
RESULTS
Clinical disease. Clinical disease was characterized by in-
creased rectal temperatures, by respiratory disease with la-
bored breathing and sneezing, and by reduced average daily
weight gain after PRRSV challenge. The NV-PRRSV, PCV2-
V-PRRSV, and V-PRRSV groups had increased rectal tem-
peratures after PRRSV challenge. The temperatures ranged
from 40.1 to 41.8°C with peak temperatures at 5 to 7 days after
PRRSV challenge, with 80% of the pigs being febrile. After
challenge, there were significant (P  0.001) differences in
mean rectal temperatures between groups. The NV-PRRSV
pigs had the highest rectal temperatures, and all PRRSV-
challenged groups had significantly higher rectal temperatures
than did non-PRRSV-inoculated groups.
After PRRSV challenge, the highest average group respira-
tory scores were observed for the NV-PRRSV pigs (mean
score, 1.6), the PCV2-V-PRRSV pigs (mean score, 1.2), and
the V-PRRSV pigs (mean score, 1.1), which were all signifi-
cantly (P 0.0001) higher than the scores for the other groups
but not different from each other (data not shown).
The average daily weight gain is summarized in Table 2.
From the day of PRRSV vaccination to the day of PRRSV
challenge, the average daily gains were not significantly (P 
0.24) different between the groups. From the day of PRRSV
challenge to the day of necropsy, NV-PRRSV pigs had signif-
icantly (P 0.0001) lower average daily gains than did all other
groups. The average weight gains for the V-PRRSV and the
PCV2-V-PRRSV pigs were not different from each other but
were significantly (P  0.001) lower than for the control,
PCV2, PCV2-V, and V groups. When the total average weight
gains for the period from the day of PRRSV vaccination until
necropsy were evaluated, the NV-PRRSV and PCV2-V-
PRRSV pigs had significantly (P  0.001) lower average daily
gains than did the control and V groups.
Antibody response. All pigs were free of PRRSV-specific an-
tibodies at arrival in the research facility. The V-PRRSV, PCV2-
V-PRRSV, and PCV2-V pigs seroconverted to PRRSV between
7 and 21 days postvaccination. The mean group S/P ratios were
numerically but not significantly lower in the PCV2-V-PRRSV
group (Fig. 1) and in the V-PCV2 group than they were in the
V-PRRSV group. The nonvaccinated and non-PRRSV-chal-
lenged groups (control and PCV2) remained seronegative until
the termination of the experiment. The NV-PRRSV pigs sero-
converted within 2 weeks after PRRSV challenge. Neutralizing
antibodies to SDSU73 were not detected in any of the vaccinated
pigs prior to PRRSV challenge.
At arrival, the majority of the pigs had maternal antibodies to
PCV2, which waned over the following weeks. On the day of
PCV2 inoculation, all pigs were negative for PCV2-specific anti-
bodies. Seroconversion to PCV2 was observed at the termination
of the study in 10 of 10 PCV2-V-PRRSV pigs, 9 of 10 PCV2-V
pigs, and 7 of 10 PCV2 pigs. The mean S/P ratios were signifi-
cantly (P  0.001) higher in the PCV2-V-PRRSV (0.87  0.08)
group than in the PCV2 (0.41 0.09) and PCV2-V (0.49 0.05)
groups.
Amount and incidence of PRRSV RNA detection. The con-
trol and PCV2 groups were negative for PRRSV RNA in
serum and lung lavage fluid (Table 3). The incidences of
PRRSV-viremic pigs were 9 of 9 for NV-PRRSV, 9 of 10 for
V-PRRSV, 10 of 10 for PCV2-V-PRRSV, 3 of 10 for PCV2-V,
and 2 of 10 for the V group on DPI 7. The incidences of
PRRSV RNA-positive pigs were 8 of 9 for NV-PRRSV, 6 of 10
for V-PRRSV, 5 of 10 for PCV2-V-PRRSV, 0 of 10 for
TABLE 2. Average daily weight gains for the period from
vaccination to prior to inoculation with PRRSV, the period
after PRRSV challenge, and the entire period from
vaccination to necropsy
Group
ADG for a:
ADG 1 ADG 2 ADG 3
Control 774.9  28.8 1,277.4  33.3A 875.4  29.1A
NV-PRRSV 793.2  36.1 388.2  108.0B 694.9  36.1B
V-PRRSVb 813.5  23.6 783.3  47.9C 807.5  20.8AB
PCV2-V-PRRSVb 715.0  34.0 711.0  37.2C 714.2  31.0B
PCV2 732.2  38.8 1,099.3  32.3AD 805.6  33.1AB
PCV2-V b 739.6  26.8 1,044.3  41.1D 800.6  22.5AB
Vb 797.3  36.5 1,138.2  46.8AD 865.5  35.2A
a ADG, average daily weight gain (group means g  standard errors); ADG
1, period from vaccination to prior to inoculation with PRRSV; ADG 2, period
after PRRSV challenge; ADG 3, the entire period from vaccination to necropsy.
Values within a column with no common superscript are significantly (P 
0.0001) different.
b Vaccinated with Ingelvac PRRS ATP MLV vaccine (Boehringer Ingelheim
Vetmedica, Inc., St. Joseph, MO).
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PCV2-V, and 0 of 10 for V group on DPI 14. The amount of
PRRSV RNA in serum was significantly (P  0.001) higher in
the NV-PRRSV group than in the V-PRRSV and PCV2-V-
PRRSV groups at 7 and at 14 days after PRRSV infection (Fig.
2). The incidence of PRRSV RNA-positive lavage fluids is
summarized in Table 3.
Amount and incidence of PCV2 DNA detection. At the day
of PRRSV challenge, PCV2 DNA was detected in 8 of 10
PCV2-V-PRRSV pigs, in 7 of 10 PCV2-V pigs, and in 6 of 10
PCV2 pigs. At the day of necropsy, PCV2 DNA was detected
in 9 of 10 PCV2-V-PRRSV pigs, in 7 of 10 PCV2-V pigs, and
in 5 of 10 PCV2 pigs. All PCV2-infected pigs were positive for
PCV2 DNA on BAL fluid (Table 3). The amounts of PCV2
antigen were not different (P  0.05) among the three groups.
Macroscopic lesions. PRRSV-induced macroscopic lung le-
sions were characterized by failure of the lungs to collapse and
by focal-to-diffuse, mottled-tan, well-to-poorly demarcated
areas of pneumonia. There were significant differences among
groups in the mean percentages of lung macroscopically af-
fected by pneumonia, as summarized in Table 3.
FIG. 1. Mean group anti-PRRSV-specific antibodies as determined by ELISA. A sample-to-positive ratio of equal to or greater than 0.4 is
considered to be positive. Error bars represent standard errors.
TABLE 3. Incidence and severity of macroscopic and microscopic lung lesions and presence of PRRSV and PCV2
nucleic acids and antigens in lungs a
Group
Result for indicated lung lesionb:
Detected presence of:
PRRSV PCV2
Macroscopic Microscopic BAL fluidPCR IHC
BAL fluid
PCR IHC
Control 1/10 (0.3  0.3)A 10/10 (1.2  0.1)A 0/10 NAc NA NA
NV-PRRSV 9/9 (50.1  3.1)B 9/9 (4.6  0.4)B 9/9 8/9 NA NA
V-PRRSVd 10/10 (13.2  2.6)C 10/10 (2.5  0.3)AC 10/10 0/10 NA NA
PCV2-V-PRRSVd 10/10 (31.7  5.0)D 10/10 (3.3  0.5)BC 10/10 4/10 10/10 0/10
PCV2 4/10 (1.0  0.6)A 10/10 (1.2  0.1)A 0/10 NA 10/10 0/10
PCV2-V d 3/10 (2.2  1.3)AC 10/10 (1.8  0.2)A 8/10 0/10 10/10 0/10
Vd 0/10 (0.0  0.0)A 8/10 (1.2  0.3)A 2/10 0/10 NA NA
a Detected by PCR on BAL fluid and IHC at 14 days after PRRSV challenge.
b Data presented as incidences/total and group means  standard errors (for macroscopic lesions, mean of the percentage of lung grossly affected by lesions ranging
from 0 to 100%; for microscopic lesions, mean of the interstitial pneumonia score ranging from 0 normal to 6 severe, diffuse). Values within a column with no
common superscript represent significantly (P  0.05) different group means.
c NA, not applicable.
d Vaccinated with Ingelvac PRRS ATP MLV vaccine (Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO).
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Microscopic lesions. PRRSV challenge induced moderate-
to-severe lung lesions characterized by type 2 pneumocyte hy-
pertrophy and hyperplasia, septal infiltration with mononu-
clear cells, and increased amounts of necrotic alveolar exudate.
No lesions or mild lung lesions characterized by septal infiltra-
tion with mononuclear cells and mild peribronchiolar fibropla-
sia and histiocytic infiltrates were observed for singular PCV2-
inoculated pigs in this study, consistent with our previous
studies (32, 36).
PRRSV and PCV2 antigen in lungs. The incidence of
PRRSV and PCV2 antigen detection in lungs as determined by
IHC stains is summarized in Table 3. NV-PRRSV pigs had a
significantly (P  0.001) higher incidence of PRRSV antigen
detection than did all other groups except PCV2-V-PRRSV.
DISCUSSION
PCV2 infection is widespread, and PCV2 is now commonly
associated with various conditions in pigs, such as PMWS,
enteritis, abortion, and respiratory disease. Another important
impact of PCV2 may actually be its adverse effect on the
immune system in the form of compromising the development
of a protective immune response to commercial vaccines com-
monly used on pigs around the time of PCV2 infection. PCV2
infection commonly occurs in pigs at 6 to 12 weeks of age in the
United States (37). Vaccines commonly used at that time in-
clude vaccines for Mycoplasma hyopneumoniae, swine influ-
enza virus, and PRRSV. PRDC is a major problem in the pig
industry, and PRRSV is the most commonly associated pri-
mary pathogen in PRDC. Coinfections with PRRSV and
PCV2 are commonly observed in the field (37, 49).
The overall goal of this study was to investigate the effect of
PCV2 infection on the efficacy of the PRRSV MLV vaccine for
protecting pigs against PRRSV-induced clinical disease and
lesions. The vaccination protocol used in this study has previ-
ously been shown to be effective in reducing clinical disease
and lesions associated with PRRSV SDSU73 infection (33).
The effects of other immunomodulating pathogens, such as
PRRSV (11, 22) or Trypanosoma evansi (20), on vaccine effi-
cacy have been investigated. Pigs were inoculated with a Eu-
ropean PRRSV strain, vaccinated with a pseudorabies virus
vaccine 2 weeks later, and challenged with pseudorabies virus
10 weeks after PRRSV inoculation. The results of that study
indicated that the lymphoproliferative response was quicker
and longer in pigs that were not previously infected by PRRSV.
However, PRRSV infection did not inhibit the vaccine efficacy
(11). Another study investigated the effect of PRRSV infection
on the antibody response to classical swine fever virus (CSFV)
vaccination (22). In that study, pigs were vaccinated 2 days
after PRRSV inoculation and it was found that the PRRSV-
inoculated pigs had significantly lower levels of anti-CSFV
antibodies than did non-PRRSV-inoculated pigs within 3 to 5
weeks after vaccination. Pigs infected with T. evansi and vac-
cinated 4 weeks later against CSFV and challenged 12 weeks
after T. evansi infection with CSFV had significantly reduced
antibody response compared to noninfected control pigs. How-
ever, there was no effect on growth performance or feed con-
version (20).
In this study, differences in immunoglobulin G antibody
response or in the presence of neutralizing antibodies against
PRRSV were not observed between V-PRRSV and PCV2-V-
PRRSV pigs. However, we did observe a significant (P  0.05)
increase in PRRSV-associated macroscopic lung lesions, a
higher incidence of PRRSV antigen in lung sections, and more-
severe microscopic PRRSV-associated lung lesions in pigs that
were subclinically infected by PCV2 at the time of PRRSV
vaccination compared to those for pigs that were not infected
with PCV2.
PRRSV vaccination typically does not prevent PRRSV in-
fection in vaccinated pigs. Moreover, in this study we used a
quantitative RT-PCR method, which is more sensitive than a
regular RT-PCR assay, and detection of small amounts of
PRRSV RNA in pigs exposed to PRRSV at some time in their
life is expected. Comparison of the amounts of PRRSV nucleic
acids in BAL fluid was not attempted since we did not use an
internal control and the collection of lavage fluid strongly de-
pends on the technique (i.e., the amount of fluid put into the
lungs, the lung lobes lavaged, and the amount of fluid recov-
ered). To better characterize the amount of PRRSV present in
the lungs, we did IHC stains for PRRSV and found positive
animals only in the NV-PRRSV group and in the PCV2-V-
PRRSV group.
Previous studies have investigated the interaction of PCV2
and PRRSV in experimental models using colostrum-deprived
pigs, cesarean-derived/colostrum-deprived (CDCD) pigs, or
conventional pigs. In all these models, PCV2 and PRRSV
inoculations were done within a narrow time window (same
day, or within one week). Allan et al. (4) inoculated 1- to
2-day-old colostrum-deprived pigs with PCV2 and PRRSV and
observed upregulation of PCV2 in coinfected pigs. The repli-
cation and distribution of PRRSV in concurrently infected pigs
were not enhanced compared to those for single PRRSV-
infected pigs (4). Harms et al. (19) coinfected 3-week-old
CDCD pigs with PCV2 and PRRSV and showed that PCV2
infection increased the severity of PRRSV-induced interstitial
pneumonia in CDCD pigs. Rovira et al. (39) inoculated
5-week-old conventional pigs with PRRSV and 7 days later
with PCV2 and confirmed that PRRSV infection enhances
PCV2 replication. A longer duration of PRRSV viremia and a
higher proportion of viremic pigs were observed in the coin-
fected pigs than in singular PRRSV-infected pigs (39). In the
current study, PCV2 infection and PRRSV challenge were
FIG. 2. Mean log-transformed group PRRSV genomic copies.
Error bars represent standard errors. *, significant (P  0.001) differ-
ences between groups.
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done 6 weeks apart, since we were most interested in the
PCV2-PRRSV MLV vaccine interaction. We did not expect to
observe a PRRSV-PCV2 interaction since we know from past
PCV2 studies that PCV2-associated lesions typically peak at 2
to 3 weeks postinoculation and usually become minimal or
resolved by 4 to 6 weeks postinoculation (34, 35). Low levels of
PCV2 DNA were present at the time of PRRSV challenge as
determined by real-time PCR. However, all lung sections were
negative for PCV2 antigen, as determined by IHC staining,
suggesting that the lung lesions were not due to PCV2.
The interval of 2 weeks between PCV2 inoculation and
PRRSV MLV vaccination was chosen because at this time we
frequently observe large amounts of PCV2 genomic copies in
serum in our pig model. A relation between PCV2 DNA load
and amount of PCV2 antigen in lymphoid lesions has been
demonstrated previously (31). In addition, Nielsen et al. (29)
found that the white blood cell counts and the mean lympho-
cyte counts were significantly decreased at 10 DPI following
experimental PCV2 infection compared to those of uninfected
controls. Rovira et al. (39) found maximal PCV2 DNA loads in
the serum of experimentally PCV2-infected pigs at 21 DPI. In
contrast, Allan et al. (3) observed minimal amounts of PCV2
antigen in mesenteric lymph nodes starting at 10 DPI with
increasing density and distribution of PCV2 antigen at 14, 17,
21, and 26 DPI.
Krakowka et al. (21) reported evidence that strong immu-
nostimulation can upregulate PCV2 infection towards mani-
festation of clinical PMWS in the gnotobiotic pig model. Sim-
ilar results were observed in the conventional pig model using
commercially available adjuvanted, killed vaccines (5, 36). To
our knowledge, PRRSV MLV vaccines have not yet been
tested for possible interaction with PCV2 infection. In the
current study, we found no evidence of vaccine-induced en-
hancement of PCV2-associated disease. None of the PCV2-V
pigs developed clinical disease, and lung sections were negative
for the presence of PCV2 antigen by IHC. Mild interstitial
pneumonia lesions were present in a portion of the PCV2-V
pigs; however, this was not different from control, PCV2, or V
pigs. Interestingly, there was a significantly (P  0.05) higher
incidence of PRRSV RNA-positive bronchoalveolar lavage
samples in the PCV2-V group than in the V group. However,
PRRSV antigen as determined by IHC was not detected in
any of the PCV2-V or V pigs. We concluded that the use of
PRRSV MLV vaccines in subclinically PCV2-infected pigs ap-
peared to be safe under the conditions of this study. This is in
contrast to the findings that PRRSV MLV vaccine predisposed
pigs to disease associated with Streptococcus suis infection (41).
In this study, we found that subclinical infection of SPF pigs
with PCV2 prior to PRRSV MLV vaccination and subsequent
PRRSV challenge resulted in increased PRRSV-induced mac-
roscopic and microscopic lung lesions. Future studies should
investigate the effect of PCV2 on cellular immunity. The ad-
verse effect of PCV2 infection on the development of protec-
tive immunity against PRRSV and other respiratory pathogen
vaccines may be an important factor in controlling PRDC and
other diseases in growing pigs.
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